Amylin up 8% as Byetta cleared of CV health risk
Shares in US drugmaker Amylin Pharmaceuticals jumped 8% to $13.47 following new data showing that Byetta (exenatide) does not cause cardiovascular side effects.
The twice-daily injection for type 2 diabetes is partnered with US drug major Eli Lilly. On the day the results were announced, March 26, shares in the firm rose 2.1% to $34.22. The findings will also be used to support the marketing application for a once-weekly version of Byetta.
The results from a meta-analysis of primary cardiovascular events across controlled clinical studies of three months duration or greater, from the Byetta injection database, showed no increased risk of cardiovascular events associated with exenatide use.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze